Stifel cuts target for Boston Scientific stock from USD 60 to USD 55

Published on 10/26/2026 at 16:06 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year. Boston Scientific stock costs EUR 40.72 on October 26, 2026.

Target, revenue and price

Stifel cut its Boston Scientific target from USD 60.00 to USD 55.00 on October 26, 2026.
Second-quarter revenue reached USD 5.44 billion, up 7.50 percent year over year.
Boston Scientific stock costs EUR 40.72 at Lang & Schwarz on October 26, 2026 at 4:01 p.m. CEST.

Boston Scientific, US1011371077, Illustration mit AI erstellt.

Boston Scientific (ISIN US1011371077) faces a lower Stifel price target as the research firm cut its view from USD 60.00 to USD 55.00 on October 26, 2026, while keeping a Buy rating, according to Investing.com. The revised target stands 20.83 percent above the USD 45.52 primary-market price cited for the same date. At Lang & Schwarz, the stock was trading at EUR 40.72 on October 26, 2026 at 4:01 p.m. CEST.

Revenue grew in the second quarter

Boston Scientific generated USD 5.44 billion in revenue in the second quarter of 2026, an increase of 7.50 percent from the same period a year earlier. The company also reported adjusted earnings per share of USD 0.86, above the USD 0.83 consensus estimate, according to MarketBeat.

Stock stays near its yearly low

The primary-market range was USD 41.38 to USD 105.65 as of October 26, 2026. The USD 45.52 price therefore stood 9.99 percent above the 52-week low and 56.90 percent below the high. Boston Scientific had a market capitalization of USD 65.96 billion and a price-to-earnings ratio of 18.51.

Results date is October 28

Boston Scientific is scheduled to report its next earnings on October 28, 2026, according to Investing.com. The analyst picture remains divided on the near-term outlook: a consensus tracked by Investing.com lists 28 analysts, with an average target of USD 57.82.

Medical devices drive the business

Boston Scientific develops medical technologies for interventional cardiology, electrophysiology, endoscopy, urology and neuromodulation. Its three main operating areas are MedSurg, Rhythm and Neuro, and Cardiovascular, giving the company exposure to several procedure-focused markets.

Boston Scientific was trading at EUR 40.72 at Lang & Schwarz on October 26, 2026 at 4:01 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Boston Scientific stock.